1. Medtech Insight

Guidant seeks US OK for cobalt chromium stent:

Guidant has submitted to the US FDA a premarket approval (PMA) application for permission to market its Multi-Link Vision coronary stent system. The device, the company's seventh-generation Multi-Link stent platform for the treatment of coronary artery disease, is constructed of a cobalt chromium alloy, enabling the stent to have thinner stent struts and enhanced deliverability while maintaining "excellent" radial strength and visibility, says the firm. The company plans to use cobalt chromium stents in future drug eluting stent platforms.

Guidant has submitted to the US FDA a premarket approval (PMA) application for permission to market its Multi-Link Vision coronary stent system. The device, the company's seventh-generation Multi-Link stent platform for the treatment of coronary artery disease, is constructed of a cobalt chromium alloy, enabling the stent to have thinner stent struts and enhanced deliverability while maintaining "excellent" radial strength and visibility, says the firm. The company plans to use cobalt chromium stents in future drug eluting stent platforms.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

BD Sees $90M Tariff Hit In Q4; 2026 Impact Reduced To $275M

 
• By Shubham Singh

BD raised its adjusted earnings per share guidance midpoint by $0.18 to a range of $14.30 to $14.45, representing growth of about 9.4% at the midpoint – an increase of approximately 1.4% over prior guidance.

Warning Letters - July 2025

The US FDA posted three warning letters in July, covering medical supply kits, wearables and orthopedics.

Brazil’s Medtechs Look To Solutions After 50% US Tariff Hit Amid ‘Scenario Of Uncertainty’

 
• By Bernard Murphy

Hopes that last-minute negotiations might exempt Brazil’s $300m medtech exports from the latest round of US tariffs have been dashed, leaving the industry braced for further market instability that countermeasures could trigger.